Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
Despite already having three products on the market, unlike many of its Hong Kong-listed peers, the drug maker is struggling to cover its daily operational costs Key Takeaways: Mabwell said…
Recent Articles
RELATED ARTICLES
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
- TransThera seeks Hong Kong IPO to sustain cancer drug research
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
- Hong Kong gains clout as preferred IPO watering hole for Chinese companies
